Cargando…
Pirfenidone alleviates cardiac fibrosis induced by pressure overload via inhibiting TGF‐β1/Smad3 signalling pathway
Cardiac fibrosis critically injured the cardiac structure and function of the hypertensive patients. However, the anti‐fibrotic strategy is still far from satisfaction. This study aims to determine the effect and mechanism of Pirfenidone (PFD), an anti‐lung fibrosis medicine, in the treatment of car...
Autores principales: | Li, Na, Hang, Weijian, Shu, Hongyang, Zhou, Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357610/ https://www.ncbi.nlm.nih.gov/pubmed/35861038 http://dx.doi.org/10.1111/jcmm.17478 |
Ejemplares similares
-
Pirfenidone Alleviates Choroidal Neovascular Fibrosis through TGF-β/Smad Signaling Pathway
por: Gao, Chuang, et al.
Publicado: (2021) -
Pirfenidone modulates macrophage polarization and ameliorates radiation‐induced lung fibrosis by inhibiting the TGF‐β1/Smad3 pathway
por: Ying, Hangjie, et al.
Publicado: (2021) -
Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways
por: Lv, Qun, et al.
Publicado: (2020) -
Inhibition of TGF-β2–Induced Trabecular Meshwork Fibrosis by Pirfenidone
por: Zhu, Xiaofeng, et al.
Publicado: (2023) -
Pirfenidone suppressed triple‐negative breast cancer metastasis by inhibiting the activity of the TGF‐β/SMAD pathway
por: Luo, Daiqin, et al.
Publicado: (2023)